Abbonarsi

Chronic pain for rheumatological disorders: Pathophysiology, therapeutics and evidence - 24/11/24

Doi : 10.1016/j.jbspin.2024.105750 
Yian Chen a, Ariana M. Nelson b, Steven P. Cohen c, d, e,
a Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, USA 
b Department of Anesthesiology and Perioperative Care, University of California-Irvine, Orange, CA, USA 
c Departments of Anesthesiology, Physical Medicine & Rehabilitation, Neurology, Psychiatry and Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA 
d Departments of Anesthesiology & Critical Care Medicine, Neurology, Physical Medicine & Rehabilitation and Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA 
e Departments of Physical Medicine & Rehabilitation and Anesthesiology, Walter Reed National Military Medical Center, Uniformed Services, University of the Health Sciences, Bethesda, MD,USA 

Corresponding author at: Northwestern Pain Management Center, 259 East Erie Street, Chicago, IL 60611, USA.Northwestern Pain Management Center259 East Erie Street, ChicagoIL60611USA

Highlights

Pain is the leading reason people seek rheumatological and orthopedic care.
The acuity of pain and disease burden have perhaps the greatest impact on prognosis, while categorization of pain into nociceptive, neuropathic and nociplastic pain influence workup and treatment, affecting therapeutic decisions at all levels of care.
Nociceptive pain responds well to treatments such as physical therapies, non-steroidal inflammatory, while adjuvants such as membrane stabilizers and antidepressants are cornerstones of the treatment for neuropathic and nociplastic pain. In general, nociplastic pain is associated with poor interventional treatment outcomes.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Pain is the leading reason people seek orthopedic and rheumatological care. By definition, most pain can be classified as nociceptive, or pain resulting from non-neural tissue injury or potential injury, with between 15% and 50% of individuals suffering from concomitant neuropathic pain or the newest category of pain, nociplastic pain, defined as “pain arising from altered nociception despite no clear evidence of actual or threatened tissue damage, or of a disease or lesion affecting the somatosensory system.” Pain classification is important because it affects treatment decisions at all levels of care. Although several instruments can assist with classifying treatment, physician designation is the reference standard. The appropriate treatment of pain should ideally involve multidisciplinary care including physical therapy, psychotherapy and integrative therapies when appropriate, and pharmacotherapy with non-steroidal anti-inflammatory drugs for acute, mechanical pain, membrane stabilizers for neuropathic and nociplastic pain, and serotonin-norepinephrine reuptake inhibitors and tricyclic antidepressants for all types of pain. For nonsurgical interventions, there is evidence to support a small effect for epidural steroid injections for an intermediate-term duration, and conflicting evidence for radiofrequency ablation to provide at least 6months of benefit for facet joint pain, knee osteoarthritis, and sacroiliac joint pain. Since pain and disability represent the top reason for elective surgery, it should be reserved for patients who fail conservative interventions. Risk factors for procedural failure are the same as risk factors for conservative treatment failure and include greater disease burden, psychopathology, opioid use, central sensitization and multiple comorbid pain conditions, poorly controlled preoperative and postoperative pain, and secondary gain.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Chronic pain, Joint, Spine, Knee, Rheumatology, Orthopedics


Mappa


© 2024  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 91 - N° 6

Articolo 105750- Dicembre 2024 Ritorno al numero
Articolo precedente Articolo precedente
  • 2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis
  • Bruno Fautrel, Joanna Kedra, Pierre-Antoine Juge, Claire Rempenault, Juliette Drouet, Jérôme Avouac, Athan Baillet, Olivier Brocq, Guillermo Carvajal Alegria, Arnaud Constantin, Emmanuelle Dernis, Cécile Gaujoux-Viala, Vincent Goëb, Jacques-Eric Gottenberg, Benoit Le Goff, Hubert Marotte, Christophe Richez, Jean-Hugues Salmon, Alain Saraux, Eric Senbel, Raphaèle Seror, Anne Tournadre, Olivier Vittecoq, Pascale Escaffre, Danielle Vacher, Philippe Dieudé, Claire Daien
| Articolo seguente Articolo seguente
  • Issues with pregnancy in systemic lupus
  • Véronique Le Guern, Gaelle Guettrot-Imbert, Anastasia Dupré, Sandrine Perol, Emmanuelle Pannier, Nathalie Morel, Nathalie Costedoat-Chalumeau

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.